NR
RPRX icon

Newfound Research’s Royalty Pharma RPRX Stock Holding History

Newfound Research’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$43K Sell
1,077
-112
-9% -$4.78K 0.11% 121
2022
Q2 		$50K Buy
+1,189
New +$48.7K 0.11% 121

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Newfound Research's RPRX Position: Q3 2022 in Review

Newfound Research reduced its Royalty Pharma (RPRX) stake by 9.4% in Q3 2022, selling an estimated $4.78K and leaving 1,077 shares worth $43K. The position accounts for 0.11% of the portfolio, ranked #121.

Newfound Research first reported a position in RPRX in Q2 2022 and has held it in 2 quarters since. The position peaked at $50K in Q2 2022. 319 funds tracked by Wall St. Rank hold RPRX as of Q3 2022.

  • Newfound Research held 1,077 shares of Royalty Pharma worth $43K as of Q3 2022.
  • Newfound Research sold 112 Royalty Pharma shares in Q3 2022, an estimated $4.78K.
  • Royalty Pharma made up 0.11% of Newfound Research's portfolio in Q3 2022, its #121 holding.
  • Newfound Research first reported a position in Royalty Pharma in Q2 2022 and has held it in 2 quarters since.
  • Newfound Research's Royalty Pharma position peaked at $50K in Q2 2022.
  • 319 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2022.

Based on Newfound Research's 13F filing for Q3 2022, filed 13 Oct 2022.